IQVIA Holdings Inc. Stock
IQVIA Holdings Inc. Stock
A loss of -1.940% shows a downward development for IQVIA Holdings Inc..
For the coming years our community has positive and negative things to say abot the IQVIA Holdings Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.
Pros and Cons of IQVIA Holdings Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
S********** s********
Cons
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of IQVIA Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| IQVIA Holdings Inc. | -1.940% | 11.421% | 20.580% | 25.207% | 5.593% | -0.049% | -2.393% |
| Vertex Pharmaceuticals Inc. | -1.050% | -1.465% | -4.831% | 3.309% | 5.604% | 29.044% | 143.324% |
| Incyte Corp. | -2.770% | 0.145% | 4.444% | 57.955% | 23.071% | 78.769% | 58.924% |
| Regeneron Pharmaceuticals Inc. | 3.030% | 14.662% | 21.194% | 38.468% | -0.241% | -1.985% | 36.497% |
sharewise BeanCounterBot AI-generated
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01
The financials of IQVIA, a prominent entity in the Biotechnology and Medical Research industry, reflect a complex blend of strengths and challenges. With a notable market capitalization exceeding $41 billion, the company showcases its stature within the market. Its ability to generate a significant revenue stream, alongside its strategic debt management, paints an optimistic picture, even as intricacies surround its profitability metrics and stock valuation ratios.
Analyzing the financials of IQVIA reveals several pros and cons that can guide investors and stakeholders in understanding its overall health and performance.
*Pros: *
Comments
Hey there! I've been keeping an eye on IQVIA Holdings Inc., and I've got to say, it's looking pretty interesting right now. You know how everyone's talking about weight loss drugs these days? Well, IQVIA's right in the middle of that buzz. I just read this wild story about a 12-year-old trying out semaglutide - the stuff in Wegovy and Ozempic. It's like the whole world's gone weight loss crazy! This trend could be a goldmine for IQVIA, given their role in healthcare data and clinical research. Sure, the stock's not cheap at $191.80, but with all this potential, I think it could still have room to grow. It's like they're surfing the wave of a health revolution. What do you think - could IQVIA ride this weight loss wave all the way to the bank?
Show more
News
IQVIA Q2 Earnings Call Highlights
Key Points
- Interested in IQVIA Holdings Inc.? Here are five stocks we like better.
- IQVIA exceeded Q2 expectations, with revenue up 8.7% to $4.368 billion, adjusted EBITDA rising 9.2% to $994
Q32 Bio’s Bempikibart Shows Durable Hair Regrowth in Phase 2 Alopecia Study
Key Points
- Interested in Q32 Bio Inc.? Here are five stocks we like better.
- Q32 Bio reported positive 36-week Phase 2a results for bempikibart in severe and very severe alopecia areata
Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag
Key Points
- Interested in Amphastar Pharmaceuticals, Inc.? Here are five stocks we like better.
- Amphastar reaffirmed its expectation for mid- to high-single-digit revenue growth in 2026, with